Business Today
Loading...

Remdesivir inches closer to EU's initial authorisation as coronavirus treatment

European Medicines Agency (EMA) has already recommended the compassionate use of remdesivir, which allows a drug to be administered to patients even before it has been fully authorised

twitter-logoReuters | May 18, 2020 | Updated 16:16 IST
Remdesivir inches closer to EU's initial authorisation as coronavirus treatment

The head of the European Union's medicines agency Guido Rasi said on Monday an initial authorisation for U.S. pharmaceutical company Gilead's remdesivir as a COVID-19 treatment could be granted in coming days.

The European Medicines Agency (EMA) has already recommended the compassionate use of remdesivir, which allows a drug to be administered to patients even before it has been fully authorised.

"It might be that a conditional market authorisation can be issued in the coming days," Rasi told a hearing in the EU Parliament in Brussels.

Apart from remdesivir, Rasi said other possible treatments against COVID-19 that may be available fast are those based on monoclonal antibodies, which can "neutralize" the new coronavirus (SARS-CoV-2) that causes the illness COVID-19.

Also read: Coronavirus vaccine: Multiple trials show positive results but concerns about timeframe remain

Also read: Coronavirus vaccine update: Moderna, Novavax lead race; Chinese firm builds largest vaccine plant

Youtube
  • Print

  • COMMENT
BT-Story-Page-B.gif
A    A   A
close